Duquesne Family Office LLC
Family OfficePosition in GLUE — Monte Rosa Therapeutics, Inc.
CIK 1536411
New York, NY
Position in GLUE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,201,920
New position
Shares Held
297,600
first reported quarter
Ownership
0.349%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#46
of 193 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Duquesne Family Office LLC holds $548,000,096 across 17 Biotechnology names. GLUE ranks #13 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
1,424,690 | $151,900,447 | |
| 2 | NAMS |
NewAmsterdam Pharma Co N.V.
|
3,070,146 | $104,047,247 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
399,587 | $74,834,653 | |
| 4 | CAI |
Caris Life Sciences, Inc.
|
1,894,450 | $33,759,099 | |
| 5 | NUVB |
Nuvation Bio Inc.
|
4,539,800 | $25,786,064 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
208,900 | $25,606,962 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
2,784,110 | $23,303,000 | |
| 8 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
203,618 | $22,607,706 |
All Filings in GLUE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,201,920 | 297,600 | Shares | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||